PM2.5 Exposure and Asthma Development: The Key Role of Oxidative Stress

Liu, Kaimeng; Hua, Shucheng; Song, Lei

doi:https://doi.org/10.1155/2022/3618806

Oxidative Medicine and Cellular Longevity

On this page

Abstract Introduction Conclusion Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Special Issue

Oxidative Stress and Antioxidant Strategies in Inflammatory Lung Diseases

View this Special Issue

Review Article | Open Access

Volume 2022 | Article ID 3618806 | https://doi.org/10.1155/2022/3618806

PM2.5 Exposure and Asthma Development: The Key Role of Oxidative Stress

Kaimeng Liu,¹Shucheng Hua,¹and Lei Song¹

Academic Editor: Alin Ciobica

Received15 Jan 2022

Accepted24 Mar 2022

Published04 Apr 2022

Abstract

Oxidative stress is defined as the imbalance between reactive oxygen species (ROS) production and the endogenous antioxidant defense system, leading to cellular damage. Asthma is a common chronic inflammatory airway disease. The presence of asthma tends to increase the production of reactive oxygen species (ROS), and the antioxidant system in the lungs is insufficient to mitigate it. Therefore, asthma can lead to an exacerbation of airway hyperresponsiveness and airway inflammation. PM2.5 exposure increases ROS levels. Meanwhile, the accumulation of ROS will further enhance the oxidative stress response, resulting in DNA, protein, lipid, and other cellular and molecular damage, leading to respiratory diseases. An in-depth study on the relationship between oxidative stress and PM2.5-related asthma is helpful to understand the pathogenesis and progression of the disease and provides a new direction for the treatment of the disease. This paper reviews the research progress of oxidative stress in PM2.5-induced asthma as well as highlights the therapeutic potentials of antioxidant approaches in treatment of asthma.

1. Introduction

Asthma is a common chronic inflammatory airway disease that affected an estimated 358 million people in 2015, and it can affect both children and adults [1]. Although the prevalence, severity, and mortality of asthma vary globally, it remains one of the most common chronic diseases that cause significant morbidity and mortality [2], which has posed a serious threat to human health and economic and social development. Even in America, asthma-related exacerbations are reported to result in about 2 million emergency department (ED) visits and 500,000 hospitalizations each year [3].

Asthma is a complex and chronic inflammatory disease of the airways with heterogeneity in etiology, pathogenesis, clinical manifestations, and prognosis. Airway inflammation, airway hyperresponsiveness, and airway remodeling are recognized as the central pathophysiological features of asthma. In recent years, oxidative stress in asthma has drawn more and more attention due to the increasing and ever-growing environmental concerns. Environmental factors such as pollutants and (non)ionizing radiation can produce many ROS, resulting in oxidative stress [4]. Oxidative stress may attack lipids, proteins, and DNA, with deleterious consequences for respiratory diseases. Furthermore, many oxygen free radicals are produced during inflammatory cell recruitment and activation in asthma, thus triggering lipid peroxidation and causing inflammatory responses as well as tissue damage [5].

In recent years, epidemiological studies have strongly suggested that an increased risk of asthma exacerbations is associated with elevated exposure to air pollution, especially PM2.5 exposure [6]. Substantial epidemiological investigations have revealed that exposure to PM2.5 is closely correlated to the progression of numerous respiratory diseases, leading to airway inflammation, a decline in lung function, and exacerbation and progression of chronic obstructive pulmonary disease (COPD) and asthma [7–11]. Many experiments have proved that PM2.5 exposure contributes to the increased risk of respiratory infections [12–16]. Furthermore, PM2.5 exposure has long been associated with increased morbidity and mortality from lung diseases such as COPD and asthma [6, 17]. Numerous studies have shown that PM2.5 exposure could produce excessive ROS and thus reduce antioxidant enzyme activities, which results in oxidative stress in cells [18, 19].

PM2.5 exposure can significantly increase the level of oxidative stress, which has an important role in the development of asthma. This paper expounds on the effects of oxidative stress on PM2.5 and asthma, demonstrating how oxidative stress affects airway inflammation, airway hyperresponsiveness, and airway remodeling in the development of asthma under PM2.5 exposure.

2. The Presence of Oxidative Stress in Asthma

Oxidative stress is defined as the imbalance between ROS production and the endogenous antioxidant defense system, leading to cellular damage [20]. The presence of asthma tends to increase ROS production, and the antioxidant system in the lungs is insufficient to mitigate it. Therefore, asthma can lead to the body under oxidative stress, which exasperates airway hyperresponsiveness and airway inflammation (Figure 1). ROS and reactive nitrogen species (RNS) play vital roles in regulating oxidative stress. Meanwhile, ROS is involved in the onset of inflammatory responses by impacting cell-signaling proteins, such as NF-Κb, TLR, MAPKs, and Keap1-Nrf2-ARE [21–23].

Figure 1

The oxidative and antioxidant imbalance in asthma. In asthma, ROS derived from inflammatory cells (such as epithelial cells, macrophages, neutrophils, and eosinophils) and environmental factors. These inflammatory cells generate amounts of ROS through mitochondrial respiration, NADPH oxidase, and a xanthine oxidase system. The antioxidant enzyme (SOD, CAT, and GPX) activity and the nonenzymatic antioxidants (such as vitamin C, vitamin E, and urate) are reduced in asthma lung. The imbalance regulates various inflammatory factor releases of inflammatory cells, activating inflammatory response and promoting the development and progression of asthma. ROS: reactive oxygen species; NADPH: nicotinamide adenine dinucleotide phosphate; SOD: superoxide dismutase; CAT: catalase; GPX: glutathione peroxidase.

2.1. Source of ROS and RNS

ROS is primarily composed of superoxide anion (O2^⋅-), hydroxyl radical (^⋅OH), and hydrogen peroxide (H₂O₂) [24]. Both endogenous and exogenous sources can produce ROS. Endogenous ROS are composed of mitochondrial respiration, NADPH, and a xanthine oxidase system [5]. Asthma is characterized by chronic inflammatory responses in the airways, in which multiple inflammatory cells are recruited and activated, such as macrophages, neutrophils, and eosinophils. These inflammatory cells and epithelial cells generate large amounts of ROS [5]. O2^⋅- is formed by the process of reduction of molecular oxygen mediated by an endogenous source and which is broken down by the superoxide dismutase (SOD) into H₂O₂. The Fenton reaction produces the highly reactive and toxic hydroxyl radical (^⋅OH) when H₂O₂ reacts with some transition metals (e.g., Fe2+ and Cu+) [25, 26]. Furthermore, neutrophils and eosinophils release cytotoxic granule proteins, such as myeloperoxidase (MPO) and eosinophil peroxidase (EPO), which catalyze the formation of hypochlorous acid (HOCl) from H₂O₂ in the presence of chloride (Cl-) [20, 26]. HOCl is a potent oxidant that kills pathogens in the airways [27]. Exogenous ROS is mainly related to environmental factors, such as smoking, ozone, particulates, and ionizing radiation [26]. These environmental triggers produce many ROS and stimulate inflammatory cells to produce large amounts of TNF-α, IL-6, and IL-1β, resulting in impaired airway epithelium and capillary endothelial barrier function, resulting in lung injury [28].

Nitric oxide (NO), nitric dioxide (NO₂), nitrous acid (HNO₂), and dinitrogen tetroxide (N₂O₄) are the constituents of RNS [29]. The level of fractional exhaled nitric oxide (FeNO) is well recognized as elevated in asthma. Nitric oxide (NO) is produced at high levels by inducible nitric oxide synthase (iNOS) by the oxidation of L-arginine (L-Arg) to L-citrulline during bacterial/proinflammatory stimuli [30, 31]. In asthma, airway inflammation induces iNOS expression in macrophages, neutrophils, and epithelial cells [31–34]. Furthermore, cigarette smoke contains a high concentration of NO [35], one of the major oxidative stress sources in the respiratory system. Peroxynitrite anion (ONOO−) is a highly reactive oxidant species that can cause lipid oxidation and damage pulmonary epithelial cells when NO and O2^⋅- may react together [36, 37].

2.2. Antioxidants

Normally, the lungs have a complete antioxidant system divided into enzymatic and nonenzymatic reactions. The main enzymes that resist ROS are superoxide dismutase (SOD), glutathione peroxidase (GPX), glutathione-S-transferase (GST), and catalase (CAT) [24]. Nonenzymatic antioxidants include vitamins (vitamins C and E), beta carotene, glutathione, and polyphenols, among others [26]. Enzymatic antioxidants of the lungs have been found to play crucial roles in the pulmonary antioxidant defenses. SOD is widely expressed in the human lung, the first and most important line of antioxidant enzyme defense systems against ROS and reduces O2^⋅- to H₂O₂ [38, 39]. CAT and GPX are the enzymes responsible for reducing H₂O₂ to water [26, 40]. Nonenzymatic antioxidants exist in the respiratory tract lining fluids [41]. Vitamins C and E play a key role in protecting lipid peroxidation through their ability to reduce radicals [41]. GSH can scavenge ^⋅OH, H₂0₂, and HOCl by donating its electrons [26, 41]. Nevertheless, it has been reported that the antioxidant enzyme activity is reduced in the asthma lung and the nonenzymatic antioxidants (such as vitamin C, vitamin E, and urate) are decreased in the respiratory tract lining fluids in asthmatics [42–44].

2.3. Redox-Sensitive Signaling Pathway

Oxidative stress affects the redox-sensitive signaling pathways and promotes the development of asthma. Low levels of oxidative stress led to the activation of the Keap1-Nrf2-ARE signaling pathway, inducing the expression of genes encoding antioxidant and detoxifying enzymes, such as heme oxygenase 1 (HO-1), SOD, CAT, and GSTs, which can eliminate the excess ROS [26, 45]. However, at higher levels of oxidative stimuli, which activate the NF-κB, TLR, and MAPK signaling pathways [21, 22, 26], TLRs are important components of the innate immune system, which lead to the activation of transcription factors like NF-κB and activator protein-1 (AP-1) through inhibitor of κB (IκB) kinase (IKK) and MAPKs [46, 47]. Consequently, the expression of inflammatory mediators is upregulated, including proinflammatory cytokines as well as prooxidant enzymes (such as NOX and iNOS), which lead to high levels of ROS. Meanwhile, TLRs also promote mitochondria to produce more ROS. Furthermore, some studies have demonstrated that ROS was also essential for TLR recruitment and dimerization, amplifying the TLR response [48–50]. NF-κB is a master redox-sensitive transcription factor that can be stimulated and inhibited by ROS at different stages of the inflammatory response. ROS could promote NF-κB and increase the expression of TNF-α, IL-6, and IL-1β in the early phases of the inflammatory response, resulting in impaired airway epithelium and capillary endothelial barrier function [51], but they could also inhibit these responses later on, assisting to induce tissue repair [47, 52]. The MAPK/AP-1 pathway plays a crucial role in oxidative stress [53]; AP-1 regulates inflammatory factors such as TNF-α, IL-6, and MCP-1ex [54], which activate an inflammatory response.

3. The Mechanisms of Oxidative Stress in Asthma

Asthma is a stepwise process characterized by the gradual accumulation of inflammatory and immune events. Airway inflammation persists throughout the disease and lays the basis for airway hyperresponsiveness and remodeling. In asthma, due to the imbalance between excessive ROS generation and reduced antioxidant defense mechanism, oxidative stress is generated. Oxidative stress plays an important role in the development and progression of asthma.

3.1. Oxidative Stress in Airway Inflammation

Asthma is mediated by type 2 and non-type 2 airway inflammations [55–57]. Type 2 inflammation is characterized by the release of T2 cytokines and is involved in the activation and migration of eosinophils, such as IL-4, IL-5, and IL-13. IL-5 promotes the synthesis of immunoglobulin E (IgE). Eosinophils then release mediators, including cytokines (such as IL-13 and IL-5), chemokines, and cytotoxic granule proteins (such as eosinophil cationic protein (ECP) and eosinophil peroxides) [58, 59], causing airway damage and the remodeling of the airway, promoting the occurrence and development of asthma. IL-4 induces IgE isotype conversion in B cells and upregulates the high-affinity IgE receptor (FcεRI) on the mast cell surface. When bound to IgE, it causes the release of inflammatory mediators, such as histamine, serotonin, prostaglandin D2, and trypsin, which increases smooth-muscle contraction and the excessive secretion of mucus [55, 60]. Non-type 2 airway inflammation is mainly implicated in the abnormal immune responses that are largely orchestrated by neutrophils, which lead to severe asthma [61]. The mechanism of airway neutrophilia in severe asthma is not known; IL-17 appears to play an important role in neutrophilic inflammation, which induces the production of chemokines and cytokines (such as G-CSF, GM-CSF, CXCL1, CXCL6, CXCL8, CSF3, IL-6, and IL-8) by bronchial epithelial cells to elicit neutrophilic airway inflammation [62–64].

ROS can be generated in asthma by inflammatory cells (such as epithelial cells, macrophages, neutrophils, and eosinophils) and lung epithelial cells [65, 66]. ROS can lead to direct oxidative damage and cell abscission of bronchial epithelial cells in asthma, which activates epithelial cells and releases cytokines such as IL-25, IL-33, and thymic stromal lymphopoietin (TSLP). These cytokines promote the production of T2 cytokines from Th2 cells and ILC2s through the activation of dendritic cells (DCs), promoting type 2 inflammation [67]. Furthermore, ROS has been implicated in activating transcription factors such as NF-κB and AP-1, which promote the release of IL-6, IL-8, and TNF-α, thus activating the T2 inflammatory response and resulting in impaired airway epithelium and capillary endothelial barrier function [21]. ROS can stimulate mast cells to release histamine, prostaglandin D2, and other proinflammatory mediators, as well as increase the production of mucus by airway epithelial cells, resulting in airway inflammation [68]. There are prostaglandin D2 receptors on the membrane surfaces of Th2 cells, mast cells, and eosinophils. When it binds to PGD2, it will promote the transmigration of Th2 cells and activate eosinophils to sites of inflammation, releasing IL-4, IL-5, and IL-13 [69] (Figure 2).

Figure 2

Oxidative stress in asthma airway inflammation. ROS are involved in the progression of asthma airway inflammation through three pathways. ① The increased release of ROS can result in direct oxidative damage to bronchial epithelial cells and cell shedding in asthma, which leads to the activation of epithelial cells and releases cytokines such as IL-25, IL-33, and TSLP. These cytokines promote the production of T2 cytokines from Th2 cells and ILC2s through the activation of dendritic cells (DCs), promoting type 2 inflammation. ② ROS have been implicated in the activation of transcription factors such as NF-kB and AP-1, which promotes the release of IL-6, IL-8, and TNF-α, thus activating T2 inflammatory response and resulting in impaired airway epithelium and capillary endothelial barrier function. ③ ROS can stimulate mast cells to release histamine, prostaglandin D2, and other proinflammatory mediators, as well as increase the production of mucus by airway epithelial cells, resulting in airway inflammation. ROS: reactive oxygen species; TSLP: thymic stromal lymphopoietin; NF-kB: nuclear factor kappa-B; AP-1: activator protein-1; MBP: myelin basic protein; ECP: eosinophil cationic protein; EPO: eosinophil peroxidase.

3.2. Oxidative Stress in Airway Hyperresponsiveness

The fundamental characteristic of the various asthma types is airway hyperresponsiveness (AHR) [70]. T2 cytokines are factors that initiate and accelerate airway hyperresponsiveness in asthma [71]. Among asthma patients, AHR has been related directly to airway smooth muscle contractility changes. Eosinophils can damage airway epithelium and induce ASM contraction and airway hyperresponsiveness by degranulating to release inflammatory mediators and granule proteins, which promote the occurrence and development of asthma. Histamine derived from mast cells, prostaglandin D2, and the cysteinyl leukotrienes are potent spasmogens of airway smooth muscle that cause bronchoconstriction and airway hyperresponsiveness [72, 73]. In addition, mast cells are directly activated by IL-33 and indirectly promote ASM contraction by upregulation of IL-13, enhancing airway responsiveness [74]. In asthma, excessive ROS production can increase lipid peroxidation and the permeability of the alveolar epithelial cells by destroying the cell membrane and promoting the release of proinflammatory cytokines from epithelial cells and alveolar macrophages, which increases the AHR [75–77].

3.3. Oxidative Stress in Airway Remodeling

Airway remodeling changes are hallmark pathologic features of asthmatic airway disease, including airway epithelial cell damage, inflammatory cell infiltration, goblet cell proliferation, mucous-gland hyperplasia, airway smooth muscle cell (ASMC) hypertrophy and migration, extracellular matrix (ECM) deposition, airway wall thickening, and increased angiogenesis [70]. Inflammation in asthma drives the pathological structural remodeling of the airways. Various cytokines, chemokines, and growth factors released by inflammatory cells and structural cells in airway tissue are crucial for airway remodeling. In asthma, airway inflammation usually involves Th2 cells, which release IL-4, IL-5, IL-9, and IL-13, and play an important role in the development of airway remodeling. The TH2-mediated inflammatory response can cause specific airway epithelial cell changes, resulting in goblet cell proliferation, epithelial hypertrophy, increased collagen deposition, excessive mucus secretion, and increased airway eosinophils [78–82]. Eosinophils are the main source of the profibrotic cytokine TGF-β, which can induce collagen synthesis, fibroblast proliferation, and myofibroblast maturation [83], and play a vital role in tissue remodeling [84]. TGF-β is a potent modulator of fibroblast and myofibroblast proliferation and differentiation and can be regulated by the Smad 2/3 and mitogen-activated protein kinase (MAPK) pathways to increase ASM cell proliferation [85, 86]. Furthermore, TGF-β has been found to play a role in enhancing the migration of ASM cells to epithelial cells to form new bundles [87]. Also, a recent study shows that autophagy plays a role in airway remodeling and can reduce lung function in asthma patients [88]. In recent years, the activation of autophagy by TGF-β1 has been recognized as a biological function of TGF-β1 [89, 90]. TGF-β can cause the accumulation of autophagosomes and the transformation of microtubule-associated protein-1 light chain 3, as well as increase the mRNA expression levels of autophagy-associated proteins such as Beclin1, Atg5, and Atg7 [90]. Autophagy is crucial for the activation of myofibroblasts and smooth muscle cells [91].

ROS stimulates the TGF-β excretion in epithelial cells [92]. ROS induces TGF-β1 and mediates the TGF-β-induced profibrotic effects, including differentiation of airway epithelial cells, subepithelial airway fibrosis, and airway smooth muscle proliferation [93]. TGF-β can also activate membrane-related oxidase, which increases ROS production [93]. TGF-β can activate NADPH oxidase (NOX) via several signaling pathways, including the Smad pathway, PI3K pathway, and MAPK pathway [93, 94]. TGF-β can also induce REDOX imbalance by inhibiting antioxidant enzymes, increasing oxidative stress levels. TGF-β1 has been shown in numerous studies to inhibit the expression of GSH, SOD, and other antioxidant enzymes [95–97] (Figure 3).

Figure 3

Oxidative stress in asthma airway remodeling. In asthma, eosinophils and airway epithelial cells are the main source of the profibrotic cytokine TGF-β, which can stimulate ROS production by activating membrane-related oxidase and inhibiting antioxidant enzymes. TGF-β can induce the activity of NAPDH oxidase (NOX) through a variety of signaling pathways, including the SMAD pathway, PI3K pathway, and MAPK pathway, and inhibit the expression of GSH, SOD, and other antioxidant enzymes. Furthermore, TGF-β can regulate autophagy by the PI3K pathway, which is crucial for the activation of myofibroblasts and smooth muscle cells. GSH: glutathione; SOD: superoxide dismutase; MAPK: mitogen-activated protein kinase; NOS2: nitric oxide synthase 2; NO: nitric oxide.

4. PM2.5-Induced Asthma

4.1. Source and Components of PM2.5

PM2.5 is one of the atmospheric aerosol pollutants [6], which originates from natural sources (such as forest fires, volcanic eruptions, dust storms, and pollen) and anthropogenic emissions (such as smoking, cooking, vehicle exhaust emissions, and fuel combustion in industrial and agricultural) [98–100]. The components of PM2.5 include heavy metals, sulfuric/nitric/ammonia salts, polycyclic aromatic hydrocarbons, fungi, spores, and viruses [99]. Due to the small particle size (<2.5 μm), large specific surface area, and strong toxin absorption capacity of PM2.5, it is recognized as a major health hazard [100]. PM2.5 can enter the lung tissue through the respiratory tract and deposit in the alveolar regions, causing inflammatory reactions in the lung.

4.2. Experimental Findings of PM2.5-Induced Asthma

In recent years, epidemiological studies strongly suggest that an increased risk of asthma exacerbations is associated with elevated exposure to air pollution, especially PM2.5 exposure [6]. PM2.5 has become one of the most significant causes of asthma. Epidemiological analyses have demonstrated an association between short- and long-term exposures to PM2.5 and increased emergency room visits and hospital admissions for asthma exacerbation [17, 101, 102]. A previous research demonstrated that the risk of a child’s hospital admission or ED visit was strongly associated with the short-term increase in PM2.5 concentration, with a 4.8% increase for every 10 μg/m³ [103]. PM2.5-induced asthma is likely affected by factors such as age, hours of outdoor activity, and local air pollution [104–107]. Asthmatic children are particularly vulnerable to the bad effects of PM2.5 [106]. With the increase in the hours of outdoor activity and the aggravation of air pollution, asthma has increased significantly, and hospital admissions are elevated [106–108].

4.3. The Mechanisms of PM2.5-Induced Asthma

Ambient PM2.5 exposure is a major risk factor for type 2 airway inflammation. PM2.5 contains biological components and organic components with REDOX activity which could induce oxidative stress, damage the airway mucosal barrier, and activate type 2 inflammatory responses, such as fungi, spores, viruses, and polycyclic aromatic hydrocarbons [42]. Oxidant stress is believed to be important in PM2.5-induced asthma pathogenesis. Previous studies found that ROS accumulation increased in lung tissues of mice exposed to PM2.5 [109], so did the expression of IL-5 and IL-6 mRNA and TNF-α and IL-6 [110].

Exposure to PM2.5 can damage airway epithelial cells, cause lung inflammation and oxidative stress, and induce the release of proinflammatory cytokines and the influx of inflammatory cells into the airway by activating different signaling pathways, including the Nrf2-keap1-ARE signaling pathway, the NF-κB signaling pathway, the MAPK signaling pathway, and the PI3K/Akt signaling pathway [111, 112]. Through the production of antioxidant enzymes and cellular protective proteins, the Nrf2 signaling pathway plays an important role in preventing airway inflammation and oxidative damage caused by PM2.5. Exposure to PM2.5 causes elevated concentrations of calcium ions in airway epithelial cells. Calcium is released from the endoplasmic reticulum and regulates various signal transduction pathways, including the activation and phosphorylation of the MAPK family, which leads to increased gene transcription (NF-κB, AP-1) that promotes the release of IL-6, IL-8, and TNF-α [113], thus activating T2 inflammatory response and inducing airway hyperreactivity.

An animal study found that prolonged exposure to PM2.5 increased TGF-β1 expression, smad2/3 phosphorylation levels, and collagen accumulation in the lungs of mice [114]. In another study, it was found that alveolar epithelial cells exposed to PM2.5 induced TGF-β expression and changed cell morphology and increased cell contractility [115]. In addition, PM2.5 exposure can induce autophagy through different molecular mechanisms, thus affecting the development of airway remodeling in asthma. A study has shown that PM2.5 promotes autophagy by affecting the expression of nitric oxide synthase 2 (NOS2) and the production of NO [89]. Other studies have shown that PM2.5 can induce autophagy in BEAS-2B cells through the PI3K/Akt/mTOR signaling pathway [90] (Figure 4).

Figure 4

The mechanisms of PM2.5-induced asthma. Exposure to PM2.5 can damage airway epithelial cells, cause lung inflammation and oxidative stress, and induce the release of proinflammatory cytokines (IL-6, IL-8, and TNF-α). Meanwhile, exposure to PM2.5 causes airway epithelial cells and the endoplasmic reticulum release calcium ions, which activates and phosphorylates the MAPK family, leading to increased gene transcription (NF-κB, AP-1), promoting the release of IL-6, IL-8, and TNF-α, thus activating T2 inflammatory response and inducing airway hyperresponsiveness. In addition, exposure to PM2.5 can induce autophagy through the PI3K/Akt/mTOR signaling pathway and elevate autophagy by affecting the expression of nitric oxide synthase 2 (NOS2) and the production of NO, as well as TGF-β1 expression, causing airway remodeling. SOD: superoxide dismutase; HO-1: heme oxygenase 1; AHR: airway hyperresponsiveness.

5. Treatment of Asthma with Traditional Chinese Medicine

Asthma is the most common chronic disease worldwide. Although long (short)-acting β-agonists and inhaled corticosteroids (ICS) are effective for asthma, there are currently no effective treatments for the disease, and many patients continue to suffer from the disease exacerbation. However, β-agonists and steroids have significant adverse effects, especially in long-acting β-agonists. Monotherapy significantly increases the risk of cardiovascular disease [116]. Recently, the application and effectiveness of using small-molecule compounds in traditional Chinese medicine for asthma have been proven by many researchers due to their distinct pharmaceutical value and fewer side effects [117]. Many studies are researching potential antiasthma drugs that have been used in traditional Chinese medicine, including polyphenols, flavonoids, alkaloids, terpenoids, emodin, cryptotanshinone, and catalpol [118] (Table 1). Nearly all of these medicines have the effect of antioxidants. The mechanisms of traditional Chinese medicine are mediated by modulation on multiple redox-sensitive signaling pathways. One study found that zingerone, which belongs to polyphenols, reduces inflammation in asthma by acting on the AMPK/Nrf2/HO-1 signaling pathway [119]. Icariin, a flavonoid, can reverse immune imbalance in asthma by downregulating GATA-3 and NF-κB, while upregulating T-bet [120]. Other research found that matrine (which belongs to alkaloids) can block asthma progression by downregulating IL-4/IL-13/STAT-6 and NF-κB [121, 122]. In a word, traditional Chinese medicine can regulate the inflammatory response by acting on the redox-sensitive signaling pathways, thereby regulating the progression of asthma, which may represent a new option for asthma treatment.

6. Conclusion

PM2.5 exposure is correlated with asthma and is closely related to asthma severity. This review elaborated on the molecular mechanism of PM2.5-induced asthma from three aspects: airway inflammation, airway hyperresponsiveness, and airway remodeling. It is worth noting that almost all of these mechanisms rely on oxidative stress balance. Oxidative stress plays a central role in the pathogenesis of PM2.5-mediated asthma. Therefore, oxidative stress should be considered in future asthma treatment. Moreover, traditional Chinese medicine, which has the effect of antioxidants, may represent a new option for asthma treatment.

Data Availability

All data used to support the findings of this study are included within the article.

Conflicts of Interest

There are no financial or other issues that might lead to conflict of interest.

Acknowledgments

This work was supported by the National Natural Science Foundation of China grant (U20A20342).

References

GBD 2015 Chronic Respiratory Disease Collaborators, “Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015,” The Lancet. Respiratory Medicine, vol. 5, no. 9, pp. 691–706, 2017.
View at: Google Scholar
J. Stern, J. Pier, and A. A. Litonjua, “Asthma epidemiology and risk factors,” Seminars in Immunopathology, vol. 42, no. 1, pp. 5–15, 2020.
View at: Publisher Site | Google Scholar
S. Croisant, “Epidemiology of asthma: prevalence and burden of disease,” Advances in Experimental Medicine and Biology, vol. 795, pp. 17–29, 2014.
View at: Publisher Site | Google Scholar
S. Bielskute, J. Plavec, and P. Podbevsek, “Impact of oxidative lesions on the human telomeric G-quadruplex,” Journal of the American Chemical Society, vol. 141, no. 6, pp. 2594–2603, 2019.
View at: Publisher Site | Google Scholar
P. Kirkham and I. Rahman, “Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy,” Pharmacology & Therapeutics, vol. 111, no. 2, pp. 476–494, 2006.
View at: Publisher Site | Google Scholar
M. Guarnieri and J. R. Balmes, “Outdoor air pollution and asthma,” Lancet, vol. 383, no. 9928, pp. 1581–1592, 2014.
View at: Publisher Site | Google Scholar
A. P. Davel, M. Lemos, L. M. Pastro et al., “Endothelial dysfunction in the pulmonary artery induced by concentrated fine particulate matter exposure is associated with local but not systemic inflammation,” Toxicology, vol. 295, no. 1-3, pp. 39–46, 2012.
View at: Publisher Site | Google Scholar
R. Habre, E. Moshier, W. Castro et al., “The effects of PM_2.5 and its components from indoor and outdoor sources on cough and wheeze symptoms in asthmatic children,” Journal of Exposure Science & Environmental Epidemiology, vol. 24, no. 4, pp. 380–387, 2014.
View at: Publisher Site | Google Scholar
K. E. Nachman and J. D. Parker, “Exposures to fine particulate air pollution and respiratory outcomes in adults using two national datasets: a cross-sectional study,” Environmental Health, vol. 11, no. 1, p. 25, 2012.
View at: Publisher Site | Google Scholar
A. Montoya-Estrada, Y. D. Torres-Ramos, A. Flores-Pliego et al., “Urban PM2.5 activates GAPDH and induces RBC damage in COPD patients,” Frontiers in Bioscience, vol. 5, pp. 638–649, 2013.
View at: Google Scholar
J. A. Gleason, L. Bielory, and J. A. Fagliano, “Associations between ozone, PM_2.5, and four pollen types on emergency department pediatric asthma events during the warm season in New Jersey: a case-crossover study,” Environmental Research, vol. 132, pp. 421–429, 2014.
View at: Publisher Site | Google Scholar
S. Sigaud, C. A. Goldsmith, H. Zhou et al., “Air pollution particles diminish bacterial clearance in the primed lungs of mice,” Toxicology and Applied Pharmacology, vol. 223, no. 1, pp. 1–9, 2007.
View at: Publisher Site | Google Scholar
C. T. Migliaccio, E. Kobos, Q. O. King, V. Porter, F. Jessop, and T. Ward, “Adverse effects of wood smoke PM(2.5) exposure on macrophage functions,” Inhalation Toxicology, vol. 25, no. 2, pp. 67–76, 2013.
View at: Publisher Site | Google Scholar
J. H. Ma, S. H. Song, M. Guo et al., “Long-term exposure to PM2.5 lowers influenza virus resistance via down- regulating pulmonary macrophage Kdm6a and mediates histones modification in IL-6 and IFN-β promoter regions,” Biochemical and Biophysical Research Communications, vol. 493, no. 2, pp. 1122–1128, 2017.
View at: Publisher Site | Google Scholar
C. E. Rivas-Santiago, S. Sarkar, P. Cantarella IV et al., “Air pollution particulate matter alters antimycobacterial respiratory epithelium innate immunity,” Infection and Immunity, vol. 83, no. 6, pp. 2507–2517, 2015.
View at: Publisher Site | Google Scholar
N. Mushtaq, M. Ezzati, L. Hall et al., “Adhesion of Streptococcus pneumoniae to human airway epithelial cells exposed to urban particulate matter,” Journal of Allergy and Clinical Immunology, vol. 127, no. 5, pp. 1236–1242.e2, 2011.
View at: Publisher Site | Google Scholar
M. B. Rice, P. L. Ljungman, E. H. Wilker et al., “Long-term exposure to traffic emissions and fine particulate matter and lung function decline in the Framingham heart study,” American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 6, pp. 656–664, 2015.
View at: Publisher Site | Google Scholar
Y. Zhao, L. Jin, Y. Chi, J. Yang, Q. Zhen, and H. Wu, “Fine particulate matter leads to unfolded protein response and shortened lifespan by inducing oxidative stress in C. elegans,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 2492368, 10 pages, 2019.
View at: Google Scholar
S. A. Weichenthal, K. Godri-Pollitt, and P. J. Villeneuve, “PM2. 5, oxidant defence and cardiorespiratory health: a review,” Environmental Health, vol. 12, no. 1, pp. 1–8, 2013.
View at: Publisher Site | Google Scholar
B. M. Hybertson, B. Gao, S. K. Bose, and J. M. McCord, “Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation,” Molecular Aspects of Medicine, vol. 32, no. 4-6, pp. 234–246, 2011.
View at: Publisher Site | Google Scholar
V. Mishra, J. Banga, and P. Silveyra, “Oxidative stress and cellular pathways of asthma and inflammation: therapeutic strategies and pharmacological targets,” Pharmacology & Therapeutics, vol. 181, pp. 169–182, 2018.
View at: Publisher Site | Google Scholar
M. R. Junttila, S. P. Li, and J. Westermarck, “Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival,” The FASEB Journal, vol. 22, no. 4, pp. 954–965, 2008.
View at: Publisher Site | Google Scholar
J. W. Kaspar, S. K. Niture, and A. K. Jaiswal, “Nrf2:INrf2 (Keap1) signaling in oxidative stress,” Free Radical Biology & Medicine, vol. 47, no. 9, pp. 1304–1309, 2009.
View at: Publisher Site | Google Scholar
D. Tang, R. Kang, T. V. Berghe, P. Vandenabeele, and G. Kroemer, “The molecular machinery of regulated cell death,” Cell Research, vol. 29, no. 5, pp. 347–364, 2019.
View at: Publisher Site | Google Scholar
M. Valko, D. Leibfritz, J. Moncol, M. T. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” The International Journal of Biochemistry & Cell Biology, vol. 39, no. 1, pp. 44–84, 2007.
View at: Publisher Site | Google Scholar
U. M. Sahiner, E. Birben, S. Erzurum, C. Sackesen, and O. Kalayci, “Oxidative stress in asthma: part of the puzzle,” Pediatric Allergy and Immunology, vol. 29, no. 8, pp. 789–800, 2018.
View at: Publisher Site | Google Scholar
J. M. Pullar, M. C. Vissers, and C. C. Winterbourn, “Living with a killer: the effects of hypochlorous acid on mammalian cells,” IUBMB Life, vol. 50, no. 4‐5, pp. 259–266, 2000.
View at: Publisher Site | Google Scholar
J. Qu, Y. Li, W. Zhong, P. Gao, and C. Hu, “Recent developments in the role of reactive oxygen species in allergic asthma,” Journal of Thoracic Disease, vol. 9, no. 1, pp. E32–E43, 2017.
View at: Publisher Site | Google Scholar
L. A. Del Rio, “ROS and RNS in plant physiology: an overview,” Journal of Experimental Botany, vol. 66, no. 10, pp. 2827–2837, 2015.
View at: Publisher Site | Google Scholar
M. A. Cinelli, H. T. Do, G. P. Miley, and R. B. Silverman, “Inducible nitric oxide synthase: regulation, structure, and inhibition,” Medicinal Research Reviews, vol. 40, no. 1, pp. 158–189, 2020.
View at: Publisher Site | Google Scholar
R. Minhas, Y. Bansal, and G. Bansal, “Inducible nitric oxide synthase inhibitors: a comprehensive update,” Medicinal Research Reviews, vol. 40, no. 3, pp. 823–855, 2020.
View at: Publisher Site | Google Scholar
Q. Hamid, D. R. Springall, V. Riveros-Moreno et al., “Induction of nitric oxide synthase in asthma,” Lancet, vol. 342, no. 8886-8887, pp. 1510–1513, 1993.
View at: Publisher Site | Google Scholar
R. Saini and S. Singh, “Inducible nitric oxide synthase: an asset to neutrophils,” Journal of Leukocyte Biology, vol. 105, no. 1, pp. 49–61, 2019.
View at: Publisher Site | Google Scholar
F. L. Ricciardolo, “Multiple roles of nitric oxide in the airways,” Thorax, vol. 58, no. 2, pp. 175–182, 2003.
View at: Publisher Site | Google Scholar
W. A. Pryor and K. Stone, “Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite,” Annals of the New York Academy of Sciences, vol. 686, no. 1, pp. 12–27, 1993.
View at: Publisher Site | Google Scholar
A. C. Carr, M. R. McCall, and B. Frei, “Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 7, pp. 1716–1723, 2000.
View at: Publisher Site | Google Scholar
D. L. Beckman, P. Mehta, V. Hanks, W. H. Rowan, and L. Liu, “Effects of peroxynitrite on pulmonary edema and the oxidative state,” Experimental Lung Research, vol. 26, no. 5, pp. 349–359, 2000.
View at: Publisher Site | Google Scholar
I. N. Zelko, T. J. Mariani, and R. J. Folz, “Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression,” Free Radical Biology & Medicine, vol. 33, no. 3, pp. 337–349, 2002.
View at: Publisher Site | Google Scholar
P. Kleniewska and R. Pawliczak, “The participation of oxidative stress in the pathogenesis of bronchial asthma,” Biomedicine & Pharmacotherapy, vol. 94, pp. 100–108, 2017.
View at: Publisher Site | Google Scholar
J. R. Arthur, “The glutathione peroxidases,” Cellular and Molecular Life Sciences, vol. 57, no. 13-14, pp. 1825–1835, 2000.
View at: Publisher Site | Google Scholar
C. E. Cross, A. van der Vliet, C. A. O'Neill, S. Louie, and B. Halliwell, “Oxidants, antioxidants, and respiratory tract lining fluids,” Environmental Health Perspectives, vol. 102, no. 10, pp. 185–191, 1994.
View at: Google Scholar
A. Nadeem, N. Siddiqui, N. O. Alharbi, and M. M. Alharbi, “Airway and systemic oxidant-antioxidant dysregulation in asthma: a possible scenario of oxidants spill over from lung into blood,” Pulmonary Pharmacology & Therapeutics, vol. 29, no. 1, pp. 31–40, 2014.
View at: Publisher Site | Google Scholar
S. A. Comhair, W. Xu, S. Ghosh et al., “Superoxide dismutase inactivation in pathophysiology of asthmatic airway remodeling and reactivity,” The American Journal of Pathology, vol. 166, no. 3, pp. 663–674, 2005.
View at: Publisher Site | Google Scholar
F. J. Kelly, I. Mudway, A. Blomberg, A. Frew, and T. Sandstrom, “Altered lung antioxidant status in patients with mild asthma,” Lancet, vol. 354, no. 9177, pp. 482-483, 1999.
View at: Publisher Site | Google Scholar
I. Bellezza, I. Giambanco, A. Minelli, and R. Donato, “Nrf2-Keap1 signaling in oxidative and reductive stress,” Biochim Biophys Acta Mol Cell Res, vol. 1865, no. 5, pp. 721–733, 2018.
View at: Publisher Site | Google Scholar
T. Kawai and S. Akira, “The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors,” Nature Immunology, vol. 11, no. 5, pp. 373–384, 2010.
View at: Publisher Site | Google Scholar
J. Lugrin, N. Rosenblatt-Velin, R. Parapanov, and L. Liaudet, “The role of oxidative stress during inflammatory processes,” Biological Chemistry, vol. 395, no. 2, pp. 203–230, 2014.
View at: Publisher Site | Google Scholar
K. Nakahira, H. P. Kim, X. H. Geng et al., “Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts,” The Journal of Experimental Medicine, vol. 203, no. 10, pp. 2377–2389, 2006.
View at: Publisher Site | Google Scholar
M. J. Paul-Clark, S. K. McMaster, R. Sorrentino et al., “Toll-like receptor 2 is essential for the sensing of oxidants during inflammation,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 4, pp. 299–306, 2009.
View at: Publisher Site | Google Scholar
S. W. Wong, M. J. Kwon, A. M. Choi, H. P. Kim, K. Nakahira, and D. H. Hwang, “Fatty acids modulate toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner,” The Journal of Biological Chemistry, vol. 284, no. 40, pp. 27384–27392, 2009.
View at: Publisher Site | Google Scholar
I. T. Lee and C. M. Yang, “Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases,” Biochemical Pharmacology, vol. 84, no. 5, pp. 581–590, 2012.
View at: Publisher Site | Google Scholar
G. Gloire and J. Piette, “Redox regulation of nuclear post-translational modifications during NF-kappaB activation,” Antioxidants & Redox Signaling, vol. 11, no. 9, pp. 2209–2222, 2009.
View at: Publisher Site | Google Scholar
J. Zhang, X. Wang, V. Vikash et al., “ROS and ROS-mediated cellular signaling,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 4350965, 18 pages, 2016.
View at: Google Scholar
F. Xu, J. Xu, X. Xiong, and Y. Deng, “Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation,” Redox Report, vol. 24, no. 1, pp. 70–74, 2019.
View at: Publisher Site | Google Scholar
J. V. Fahy, “Type 2 inflammation in asthma -- present in most, absent in many,” Nature Reviews. Immunology, vol. 15, no. 1, pp. 57–65, 2015.
View at: Publisher Site | Google Scholar
P. G. Woodruff, B. Modrek, D. F. Choy et al., “T-helper type 2-driven inflammation defines major subphenotypes of asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 5, pp. 388–395, 2009.
View at: Publisher Site | Google Scholar
D. Robinson, M. Humbert, R. Buhl et al., “Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications,” Clinical and Experimental Allergy, vol. 47, no. 2, pp. 161–175, 2017.
View at: Publisher Site | Google Scholar
K. Nakagome and M. Nagata, “Involvement and possible role of eosinophils in asthma exacerbation,” Frontiers in Immunology, vol. 9, p. 2220, 2018.
View at: Publisher Site | Google Scholar
M. Terl, V. Sedlak, P. Cap et al., “Asthma management: a new phenotype-based approach using presence of eosinophilia and allergy,” Allergy, vol. 72, no. 9, pp. 1279–1287, 2017.
View at: Publisher Site | Google Scholar
B. N. Lambrecht, H. Hammad, and J. V. Fahy, “The cytokines of asthma,” Immunity, vol. 50, no. 4, pp. 975–991, 2019.
View at: Publisher Site | Google Scholar
R. H. Green, C. E. Brightling, G. Woltmann, D. Parker, A. J. Wardlaw, and I. D. Pavord, “Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids,” Thorax, vol. 57, no. 10, pp. 875–879, 2002.
View at: Publisher Site | Google Scholar
J. L. Simpson, T. V. Grissell, J. Douwes, R. J. Scott, M. J. Boyle, and P. G. Gibson, “Innate immune activation in neutrophilic asthma and bronchiectasis,” Thorax, vol. 62, no. 3, pp. 211–218, 2007.
View at: Publisher Site | Google Scholar
W. Al-Ramli, D. Préfontaine, F. Chouiali et al., “TH17-associated cytokines (IL-17A and IL-17F) in severe asthma,” Journal of Allergy and Clinical Immunology, vol. 123, no. 5, pp. 1185–1187, 2009.
View at: Publisher Site | Google Scholar
M. Veldhoen, “Interleukin 17 is a chief orchestrator of immunity,” Nature Immunology, vol. 18, no. 6, pp. 612–621, 2017.
View at: Publisher Site | Google Scholar
T. Xia, M. Kovochich, and A. E. Nel, “Impairment of mitochondrial function by particulate matter (PM) and their toxic components: implications for PM-induced cardiovascular and lung disease,” Frontiers in Bioscience, vol. 12, no. 1, pp. 1238–1246, 2007.
View at: Publisher Site | Google Scholar
A. Valavanidis, T. Vlachogianni, K. Fiotakis, and S. Loridas, “Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms,” International Journal of Environmental Research and Public Health, vol. 10, no. 9, pp. 3886–3907, 2013.
View at: Publisher Site | Google Scholar
T. Boonpiyathad, Z. C. Sozener, P. Satitsuksanoa, and C. A. Akdis, “Immunologic mechanisms in asthma,” Seminars in Immunology, vol. 46, p. 101333, 2019.
View at: Publisher Site | Google Scholar
M. T. Krishna, J. Madden, L. M. Teran et al., “Effects of 0.2 ppm ozone on biomarkers of inflammation in bronchoalveolar lavage fluid and bronchial mucosa of healthy subjects,” European Respiratory Journal, vol. 11, no. 6, pp. 1294–1300, 1998.
View at: Publisher Site | Google Scholar
S. S. Athari, “Targeting cell signaling in allergic asthma,” Signal Transduction and Targeted Therapy, vol. 4, no. 1, p. 45, 2019.
View at: Publisher Site | Google Scholar
R. J. Russell and C. Brightling, “Pathogenesis of asthma: implications for precision medicine,” Clinical Science (London, England), vol. 131, no. 14, pp. 1723–1735, 2017.
View at: Publisher Site | Google Scholar
A. N. Pepper, H. Renz, T. B. Casale, and H. Garn, “Biologic therapy and novel molecular targets of severe asthma,” The Journal of Allergy and Clinical Immunology. In Practice, vol. 5, no. 4, pp. 909–916, 2017.
View at: Publisher Site | Google Scholar
C. E. Brightling, P. Bradding, F. A. Symon, S. T. Holgate, A. J. Wardlaw, and I. D. Pavord, “Mast-cell infiltration of airway smooth muscle in asthma,” The New England Journal of Medicine, vol. 346, no. 22, pp. 1699–1705, 2002.
View at: Publisher Site | Google Scholar
C. E. Brightling, A. J. Ammit, D. Kaur et al., “The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 10, pp. 1103–1108, 2005.
View at: Publisher Site | Google Scholar
D. Kaur, E. Gomez, C. Doe et al., “IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk,” Allergy, vol. 70, no. 5, pp. 556–567, 2015.
View at: Publisher Site | Google Scholar
J. Ciencewicki, S. Trivedi, and S. R. Kleeberger, “Oxidants and the pathogenesis of lung diseases,” The Journal of Allergy and Clinical Immunology, vol. 122, no. 3, pp. 456–468, 2008, quiz 469-70.
View at: Publisher Site | Google Scholar
U. M. Sahiner, E. Birben, S. Erzurum, C. Sackesen, and O. Kalayci, “Oxidative stress in asthma,” World Allergy Organization Journal, vol. 4, no. 10, pp. 151–158, 2011.
View at: Publisher Site | Google Scholar
G. Valacchi, N. Magnani, B. Woodby, S. M. Ferreira, and P. Evelson, “Particulate matter induces tissue OxInflammation: from mechanism to damage,” Antioxidants & Redox Signaling, vol. 33, no. 4, pp. 308–326, 2020.
View at: Publisher Site | Google Scholar
R. Afshar, B. D. Medoff, and A. D. Luster, “Allergic asthma: a tale of many T cells,” Clinical and Experimental Allergy, vol. 38, no. 12, pp. 1847–1857, 2008.
View at: Publisher Site | Google Scholar
S. Al-Muhsen, J. R. Johnson, and Q. Hamid, “Remodeling in asthma,” The Journal of Allergy and Clinical Immunology, vol. 128, no. 3, pp. 451–462, 2011, quiz 463-4.
View at: Publisher Site | Google Scholar
J. J. Lee, M. P. McGarry, S. C. Farmer et al., “Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma,” The Journal of Experimental Medicine, vol. 185, no. 12, pp. 2143–2156, 1997.
View at: Publisher Site | Google Scholar
S. Jain-Vora, S. E. Wert, U. A. Temann, J. A. Rankin, and J. A. Whitsett, “Interleukin-4 alters epithelial cell differentiation and surfactant homeostasis in the postnatal mouse lung,” American Journal of Respiratory Cell and Molecular Biology, vol. 17, no. 5, pp. 541–551, 1997.
View at: Publisher Site | Google Scholar
Z. Zhu, R. J. Homer, Z. Wang et al., “Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production,” The Journal of Clinical Investigation, vol. 103, no. 6, pp. 779–788, 1999.
View at: Publisher Site | Google Scholar
A. B. Kay, S. Phipps, and D. S. Robinson, “A role for eosinophils in airway remodelling in asthma,” Trends in Immunology, vol. 25, no. 9, pp. 477–482, 2004.
View at: Publisher Site | Google Scholar
R. Halwani, S. Al-Muhsen, H. Al-Jahdali, and Q. Hamid, “Role of transforming growth factor–β in airway remodeling in asthma,” American Journal of Respiratory Cell and Molecular Biology, vol. 44, no. 2, pp. 127–133, 2011.
View at: Publisher Site | Google Scholar
M. Michalik, M. Pierzchalska, A. Legutko et al., “Asthmatic bronchial fibroblasts demonstrate enhanced potential to differentiate into myofibroblasts in culture,” Medical Science Monitor, vol. 15, no. 7, pp. BR194–BR201, 2009.
View at: Google Scholar
G. Chen and N. Khalil, “TGF-beta1 increases proliferation of airway smooth muscle cells by phosphorylation of map kinases,” Respiratory Research, vol. 7, no. 1, p. 2, 2006.
View at: Publisher Site | Google Scholar
I. Ito, E. D. Fixman, K. Asai et al., “Platelet-derived growth factor and transforming growth factor-beta modulate the expression of matrix metalloproteinases and migratory function of human airway smooth muscle cells,” Clinical and Experimental Allergy, vol. 39, no. 9, pp. 1370–1380, 2009.
View at: Publisher Site | Google Scholar
S. Ghavami, R. H. Cunnington, S. Gupta et al., “Autophagy is a regulator of TGF- β₁-induced fibrogenesis in primary human atrial myofibroblasts,” Cell Death & Disease, vol. 6, no. 3, article e1696, 2015.
View at: Publisher Site | Google Scholar
Y. Ding and M. E. Choi, “Regulation of autophagy by TGF-β: emerging role in kidney fibrosis,” Seminars in Nephrology, vol. 34, no. 1, pp. 62–71, 2014.
View at: Publisher Site | Google Scholar
K. Kiyono, H. I. Suzuki, H. Matsuyama et al., “Autophagy is activated by TGF-beta and potentiates TGF-beta-mediated growth inhibition in human hepatocellular carcinoma cells,” Cancer Research, vol. 69, no. 23, pp. 8844–8852, 2009.
View at: Publisher Site | Google Scholar
K. D. McAlinden, D. A. Deshpande, S. Ghavami et al., “Autophagy activation in asthma airways remodeling,” American Journal of Respiratory Cell and Molecular Biology, vol. 60, no. 5, pp. 541–553, 2019.
View at: Publisher Site | Google Scholar
G. Latella, “Redox imbalance in intestinal fibrosis: beware of the TGFβ-1, ROS, and Nrf2 connection,” Digestive Diseases and Sciences, vol. 63, no. 2, pp. 312–320, 2018.
View at: Publisher Site | Google Scholar
R. M. Liu and L. P. Desai, “Reciprocal regulation of TGF-β and reactive oxygen species: a perverse cycle for fibrosis,” Redox Biology, vol. 6, pp. 565–577, 2015.
View at: Publisher Site | Google Scholar
L. Hecker, R. Vittal, T. Jones et al., “NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury,” Nature Medicine, vol. 15, no. 9, pp. 1077–1081, 2009.
View at: Publisher Site | Google Scholar
R. M. Liu, P. K. Vayalil, C. Ballinger et al., “Transforming growth factor β suppresses glutamate-cysteine ligase gene expression and induces oxidative stress in a lung fibrosis model,” Free Radical Biology & Medicine, vol. 53, no. 3, pp. 554–563, 2012.
View at: Publisher Site | Google Scholar
H. Jardine, W. MacNee, K. Donaldson, and I. Rahman, “Molecular Mechanism of Transforming Growth Factor (TGF)-β₁-induced Glutathione Depletion in Alveolar Epithelial Cells:,” Journal of Biological Chemistry, vol. 277, no. 24, pp. 21158–21166, 2002.
View at: Publisher Site | Google Scholar
C. Michaeloudes, M. B. Sukkar, N. M. Khorasani, P. K. Bhavsar, and K. F. Chung, “TGF-β regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 300, no. 2, pp. L295–L304, 2011.
View at: Publisher Site | Google Scholar
R. Zhang, G. Wang, S. Guo et al., “Formation of urban fine particulate matter,” Chemical Reviews, vol. 115, no. 10, pp. 3803–3855, 2015.
View at: Publisher Site | Google Scholar
L. Yang, C. Li, and X. Tang, “The impact of PM2. 5 on the host defense of respiratory system,” Frontiers in Cell and Developmental Biology, vol. 8, p. 91, 2020.
View at: Publisher Site | Google Scholar
A. Valavanidis, K. Fiotakis, and T. Vlachogianni, “Airborne particulate matter and human health: toxicological assessment and importance of size and composition of particles for oxidative damage and carcinogenic mechanisms,” Journal of Environmental Science and Health. Part C, vol. 26, no. 4, pp. 339–362, 2008.
View at: Publisher Site | Google Scholar
X. Y. Zheng, H. Ding, L. N. Jiang et al., “Association between air pollutants and asthma emergency room visits and hospital admissions in time series studies: a systematic review and meta-analysis,” PLoS One, vol. 10, no. 9, article e0138146, 2015.
View at: Publisher Site | Google Scholar
D. M. Stieb, M. Szyszkowicz, B. H. Rowe, and J. A. Leech, “Air pollution and emergency department visits for cardiac and respiratory conditions: a multi-city time-series analysis,” Environmental Health, vol. 8, no. 1, p. 25, 2009.
View at: Publisher Site | Google Scholar
H. Lim, H. J. Kwon, J. A. Lim et al., “Short-term effect of fine particulate matter on children’s hospital admissions and emergency department visits for asthma: a systematic review and meta-analysis,” Journal of Preventive Medicine and Public Health, vol. 49, no. 4, pp. 205–219, 2016.
View at: Publisher Site | Google Scholar
U. Gehring, A. H. Wijga, M. Brauer et al., “Traffic-related air pollution and the development of asthma and allergies during the first 8 years of life,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 6, pp. 596–603, 2010.
View at: Publisher Site | Google Scholar
M. Brauer, G. Hoek, H. A. Smit et al., “Air pollution and development of asthma, allergy and infections in a birth cohort,” The European Respiratory Journal, vol. 29, no. 5, pp. 879–888, 2007.
View at: Publisher Site | Google Scholar
R. A. Silverman and K. Ito, “Age-related association of fine particles and ozone with severe acute asthma in New York City,” Journal of Allergy and Clinical Immunology, vol. 125, no. 2, pp. 367–373.e5, 2010.
View at: Publisher Site | Google Scholar
G. Bowatte, C. Lodge, A. J. Lowe et al., “The influence of childhood traffic-related air pollution exposure on asthma, allergy and sensitization: a systematic review and a meta-analysis of birth cohort studies,” Allergy, vol. 70, no. 3, pp. 245–256, 2015.
View at: Publisher Site | Google Scholar
A. Iskandar, Z. J. Andersen, K. Bonnelykke, T. Ellermann, K. K. Andersen, and H. Bisgaard, “Coarse and fine particles but not ultrafine particles in urban air trigger hospital admission for asthma in children,” Thorax, vol. 67, no. 3, pp. 252–257, 2012.
View at: Publisher Site | Google Scholar
G. Wang, L. Zhen, P. Lu, R. Jiang, and W. Song, “Effects of ozone and fine particulate matter (PM2.5) on rat cardiac autonomic nervous system and systemic inflammation,” Journal of Hygiene Research, vol. 42, no. 4, pp. 554–560, 2013.
View at: Google Scholar
A. L. Lambert, W. Dong, M. K. Selgrade, and M. I. Gilmour, “Enhanced allergic sensitization by residual oil fly ash particles is mediated by soluble metal constituents,” Toxicology and Applied Pharmacology, vol. 165, no. 1, pp. 84–93, 2000.
View at: Publisher Site | Google Scholar
F. Mazzoli-Rocha, S. Fernandes, M. Einicker-Lamas, and W. A. Zin, “Roles of oxidative stress in signaling and inflammation induced by particulate matter,” Cell Biology and Toxicology, vol. 26, no. 5, pp. 481–498, 2010.
View at: Publisher Site | Google Scholar
Z. Yan, Y. Jin, Z. An, Y. Liu, J. M. Samet, and W. Wu, “Inflammatory cell signaling following exposures to particulate matter and ozone,” Biochimica et Biophysica Acta, vol. 1860, no. 12, pp. 2826–2834, 2016.
View at: Publisher Site | Google Scholar
D. M. Brown, K. Donaldson, P. J. Borm et al., “Calcium and ROS-mediated activation of transcription factors and TNF-alpha cytokine gene expression in macrophages exposed to ultrafine particles,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 286, no. 2, pp. L344–L353, 2004.
View at: Publisher Site | Google Scholar
L. Z. Gu, H. Sun, and J. H. Chen, “Histone deacetylases 3 deletion restrains PM2.5-induced mice lung injury by regulating NF-κB and TGF-β/Smad2/3 signaling pathways,” Biomedicine & Pharmacotherapy, vol. 85, pp. 756–762, 2017.
View at: Publisher Site | Google Scholar
M. M. Dysart, B. R. Galvis, A. G. Russell, and T. H. Barker, “Environmental particulate (PM2. 5) augments stiffness-induced alveolar epithelial cell mechanoactivation of transforming growth factor beta,” PLoS One, vol. 9, no. 9, p. e106821, 2014.
View at: Publisher Site | Google Scholar
G. J. Rodrigo and J. A. Castro-Rodriguez, “Safety of long-acting β agonists for the treatment of asthma: clearing the air,” Thorax, vol. 67, no. 4, pp. 342–349, 2012.
View at: Publisher Site | Google Scholar
J. Li, F. Zhang, and J. Li, “The immunoregulatory effects of traditional Chinese medicine on treatment of asthma or asthmatic inflammation,” The American Journal of Chinese Medicine, vol. 43, no. 6, pp. 1059–1081, 2015.
View at: Publisher Site | Google Scholar
W. Wang, Q. Yao, F. Teng, J. Cui, J. Dong, and Y. Wei, “Active ingredients from Chinese medicine plants as therapeutic strategies for asthma: overview and challenges,” Biomedicine & Pharmacotherapy, vol. 137, p. 111383, 2021.
View at: Publisher Site | Google Scholar
Y. Zhu, C. Wang, J. Luo et al., “The protective role of zingerone in a murine asthma model via activation of the AMPK/Nrf2/HO-1 pathway,” Food & Function, vol. 12, no. 7, pp. 3120–3131, 2021.
View at: Publisher Site | Google Scholar
C. Q. Xu, J. J. Le, X. H. Duan et al., “Molecular mechanism of icariin on rat asthmatic model,” Chinese Medical Journal, vol. 124, no. 18, pp. 2899–2906, 2011.
View at: Google Scholar
Q. Fu, J. Wang, Z. Ma, and S. Ma, “Anti-asthmatic effects of matrine in a mouse model of allergic asthma,” Fitoterapia, vol. 94, pp. 183–189, 2014.
View at: Publisher Site | Google Scholar
D. Sun, J. Wang, N. Yang, and H. Ma, “Matrine suppresses airway inflammation by downregulating SOCS3 expression via inhibition of NF-κB signaling in airway epithelial cells and asthmatic mice,” Biochemical and Biophysical Research Communications, vol. 477, no. 1, pp. 83–90, 2016.
View at: Publisher Site | Google Scholar
P. S. Chauhan, D. K. Singh, D. Dash, and R. Singh, “Intranasal curcumin regulates chronic asthma in mice by modulating NF-ĸB activation and MAPK signaling,” Phytomedicine, vol. 51, pp. 29–38, 2018.
View at: Publisher Site | Google Scholar
H. Jiang, J. Duan, K. Xu, and W. Zhang, “Resveratrol protects against asthma-induced airway inflammation and remodeling by inhibiting the HMGB1/TLR4/NF-κB pathway,” Experimental and Therapeutic Medicine, vol. 18, no. 1, pp. 459–466, 2019.
View at: Publisher Site | Google Scholar
X. N. Li, L. Y. Ma, H. Ji, Y. H. Qin, S. S. Jin, and L. X. Xu, “Resveratrol protects against oxidative stress by activating the Keap-1/Nrf2 antioxidant defense system in obese-asthmatic rats,” Experimental and Therapeutic Medicine, vol. 16, no. 6, pp. 4339–4348, 2018.
View at: Publisher Site | Google Scholar
S. Wang, T. Wuniqiemu, W. Tang et al., “Luteolin inhibits autophagy in allergic asthma by activating PI3K/Akt/mTOR signaling and inhibiting Beclin-1-PI3KC3 complex,” International Immunopharmacology, vol. 94, p. 107460, 2021.
View at: Publisher Site | Google Scholar
H. J. Park, C. M. Lee, I. D. Jung et al., “Quercetin regulates Th1/Th2 balance in a murine model of asthma,” International Immunopharmacology, vol. 9, no. 3, pp. 261–267, 2009.
View at: Publisher Site | Google Scholar
A. Ge, Y. Liu, X. Zeng et al., “Effect of diosmetin on airway remodeling in a murine model of chronic asthma,” Acta Biochim Biophys Sin (Shanghai), vol. 47, no. 8, pp. 604–611, 2015.
View at: Publisher Site | Google Scholar
Y. N. Liu, W. J. Zha, Y. Ma et al., “Galangin attenuates airway remodelling by inhibiting TGF-β1-mediated ROS generation and MAPK/Akt phosphorylation in asthma,” Scientific Reports, vol. 5, no. 1, p. 11758, 2015.
View at: Publisher Site | Google Scholar
Q. Li, C. Zhai, G. Wang et al., “Ginsenoside Rh1 attenuates ovalbumin-induced asthma by regulating Th1/Th2 cytokines balance,” Bioscience, Biotechnology, and Biochemistry, vol. 85, no. 8, pp. 1809–1817, 2021.
View at: Publisher Site | Google Scholar
N. F. Ji, Y. C. Xie, M. S. Zhang et al., “Ligustrazine corrects Th1/Th2 and Treg/Th17 imbalance in a mouse asthma model,” International Immunopharmacology, vol. 21, no. 1, pp. 76–81, 2014.
View at: Publisher Site | Google Scholar
Z. Bao, S. Guan, C. Cheng et al., “A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-kappaB pathway,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 8, pp. 657–665, 2009.
View at: Publisher Site | Google Scholar
J. Miao, X. He, J. Hu, and W. Cai, “Emodin inhibits NF-kappaB signaling pathway to protect obese asthmatic rats from pathological damage via Visfatin,” Tissue & Cell, vol. 74, p. 101713, 2021.
View at: Google Scholar
J. Li, M. Zheng, C. Wang et al., “Cryptotanshinone attenuates allergic airway inflammation through negative regulation of NF-κB and p38 MAPK,” Bioscience, Biotechnology, and Biochemistry, vol. 84, no. 2, pp. 268–278, 2020.
View at: Publisher Site | Google Scholar
X. Feng, Y. Yang, Y. Zheng, J. Song, Y. Hu, and F. Xu, “Effects of catalpol on asthma by airway remodeling via inhibiting TGF-β1 and EGF in ovalbumin-induced asthmatic mice,” American Journal of Translational Research, vol. 12, no. 7, pp. 4084–4093, 2020.
View at: Google Scholar

Copyright

Copyright © 2022 Kaimeng Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1740

Downloads

1260

Citations